MoCD Type A is a rapidly progressive autosomal recessive inborn error of metabolism
Oxurion and Inceptua Group enter global license agreement for the commercialization of JETREA®
- by Inceptua
- | March 13, 2020
Press Release:
Oxurion and Inceptua Group enter global license agreement for the commercialization of JETREA®
Oxurion announces the signing of a JETREA® global license agreement with Inceptua Group.
JETREA® is a first-in-class pharmacological vitreolysis therapy approved for treatment of symptomatic vitreomacular adhesion or vitreomacular traction. It was launched in early 2013.
Patrik De Haes, M.D., CEO of Oxurion NV, said: “Today’s deal with Inceptua is in line with our plan to move the commercialization of JETREA® to a distribution and licensee model. Our worldwide license agreement with Inceptua will allow us to fully focus our organization and resources on further progressing our promising clinical pipeline of next generation non-VEGF assets for treatment of diabetic eye disease.”
For further info access full press release here: https://lnkd.in/gaJt9jT)
Heather Manna, VP, Global Regulatory Affairs, Inceptua Early Access, answers questions about Real World Data and Early Access.
Apealea is the first Cremophor-free formulation of paclitaxel approved in combination with carboplatin for ovarian cancer.